News stories about Allergan (NYSE:AGN) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.6778469380202 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald set a $180.00 price objective on shares of Allergan and gave the stock a “hold” rating in a research note on Monday, June 11th. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research note on Monday, June 11th. Bank of America raised their price objective on shares of Allergan from $209.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Credit Suisse Group set a $213.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Finally, Mizuho lifted their price target on shares of Allergan from $150.00 to $176.00 and gave the stock a “neutral” rating in a research note on Monday, June 11th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $212.15.
Shares of NYSE:AGN opened at $166.60 on Thursday. Allergan has a 52 week low of $142.81 and a 52 week high of $256.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.10. The firm has a market capitalization of $58.06 billion, a PE ratio of 10.19, a PEG ratio of 1.22 and a beta of 1.12.
Allergan (NYSE:AGN) last issued its earnings results on Monday, April 30th. The company reported $3.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.36 by $0.38. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. sell-side analysts forecast that Allergan will post 16.06 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 15th. Stockholders of record on Friday, May 18th were paid a $0.72 dividend. The ex-dividend date was Thursday, May 17th. This represents a $2.88 annualized dividend and a dividend yield of 1.73%. Allergan’s dividend payout ratio is presently 17.61%.
In other news, EVP William Meury sold 24,425 shares of the business’s stock in a transaction on Thursday, May 17th. The shares were sold at an average price of $154.59, for a total value of $3,775,860.75. The sale was disclosed in a filing with the SEC, which is available at this link. 0.37% of the stock is currently owned by insiders.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.